Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer
Context: Triple-negative breast cancer (TNBC) has poor prognosis, high mortality, and recurrence rates. Ixabepilone or ixempra could be a promising agent for TNBC, especially in the taxane-and/or anthracycline-resistant population. Aims: To evaluate the efficacy and safety of ixabepilone-based chemo...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academic Association of Pharmaceutical Sciences from Antofagasta
2024
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/117874/ http://psasir.upm.edu.my/id/eprint/117874/1/117874.pdf |
| _version_ | 1848867366746718208 |
|---|---|
| author | Azizah, Maghfira Rahma Hanum, Halida Adib Norahmawati, Eviana Fakurazi, Sharida Kawamoto, Yoshiyuki Permana, Sofy Widodo, Edwin Endharti, Agustina Tri |
| author_facet | Azizah, Maghfira Rahma Hanum, Halida Adib Norahmawati, Eviana Fakurazi, Sharida Kawamoto, Yoshiyuki Permana, Sofy Widodo, Edwin Endharti, Agustina Tri |
| author_sort | Azizah, Maghfira Rahma |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | Context: Triple-negative breast cancer (TNBC) has poor prognosis, high mortality, and recurrence rates. Ixabepilone or ixempra could be a promising agent for TNBC, especially in the taxane-and/or anthracycline-resistant population. Aims: To evaluate the efficacy and safety of ixabepilone-based chemotherapy compared to ixabepilone-free chemotherapy in TNBC patients. Methods: This review followed the preferred reporting items for systematic reviews and meta-analysis guidelines. The eligibility criteria included randomized control trials (RCTs) in 2013-2023 comparing ixabepilone-based with ixabepilone-free chemotherapy regimen in TNBC. Results: This study identified four eligible RCTs. One study showed that patients treated with ixabepilone had a significant improvement in disease-free survival, had a better response, and a lower risk of disease recurrence compared to those treated with taxane-based regimen. However, two studies showed no differences in terms of overall survival (OS), disease-free survival, and pathological complete responses rates in both treatment arms. Ixabepilone addition to capecitabine significantly prolonged progression-free survival and objective response rate in TNBC patients, but did not significantly improve OS (n= 1). Conclusions: The effectiveness and safety of ixabepilone-based chemotherapy versus ixabepilone-free treatment for triple-negative breast cancer (TNBC) patients vary among studies. More research is needed to better understand the effectiveness and safety of ixabepilone-based chemotherapy versus ixabepilone-free treatment in TNBC patients. |
| first_indexed | 2025-11-15T14:35:22Z |
| format | Article |
| id | upm-117874 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T14:35:22Z |
| publishDate | 2024 |
| publisher | Academic Association of Pharmaceutical Sciences from Antofagasta |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-1178742025-06-13T09:27:39Z http://psasir.upm.edu.my/id/eprint/117874/ Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer Azizah, Maghfira Rahma Hanum, Halida Adib Norahmawati, Eviana Fakurazi, Sharida Kawamoto, Yoshiyuki Permana, Sofy Widodo, Edwin Endharti, Agustina Tri Context: Triple-negative breast cancer (TNBC) has poor prognosis, high mortality, and recurrence rates. Ixabepilone or ixempra could be a promising agent for TNBC, especially in the taxane-and/or anthracycline-resistant population. Aims: To evaluate the efficacy and safety of ixabepilone-based chemotherapy compared to ixabepilone-free chemotherapy in TNBC patients. Methods: This review followed the preferred reporting items for systematic reviews and meta-analysis guidelines. The eligibility criteria included randomized control trials (RCTs) in 2013-2023 comparing ixabepilone-based with ixabepilone-free chemotherapy regimen in TNBC. Results: This study identified four eligible RCTs. One study showed that patients treated with ixabepilone had a significant improvement in disease-free survival, had a better response, and a lower risk of disease recurrence compared to those treated with taxane-based regimen. However, two studies showed no differences in terms of overall survival (OS), disease-free survival, and pathological complete responses rates in both treatment arms. Ixabepilone addition to capecitabine significantly prolonged progression-free survival and objective response rate in TNBC patients, but did not significantly improve OS (n= 1). Conclusions: The effectiveness and safety of ixabepilone-based chemotherapy versus ixabepilone-free treatment for triple-negative breast cancer (TNBC) patients vary among studies. More research is needed to better understand the effectiveness and safety of ixabepilone-based chemotherapy versus ixabepilone-free treatment in TNBC patients. Academic Association of Pharmaceutical Sciences from Antofagasta 2024-03-24 Article PeerReviewed text en cc_by_nc_4 http://psasir.upm.edu.my/id/eprint/117874/1/117874.pdf Azizah, Maghfira Rahma and Hanum, Halida Adib and Norahmawati, Eviana and Fakurazi, Sharida and Kawamoto, Yoshiyuki and Permana, Sofy and Widodo, Edwin and Endharti, Agustina Tri (2024) Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer. Journal of Pharmacy and Pharmacognosy Research, 12 (4). pp. 722-734. ISSN 0719-4250 https://jppres.com/jppres/ixabepilone-and-triple-negative-breast-cancer/ 10.56499/jppres23.1869_12.4.722 |
| spellingShingle | Azizah, Maghfira Rahma Hanum, Halida Adib Norahmawati, Eviana Fakurazi, Sharida Kawamoto, Yoshiyuki Permana, Sofy Widodo, Edwin Endharti, Agustina Tri Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer |
| title | Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer |
| title_full | Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer |
| title_fullStr | Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer |
| title_full_unstemmed | Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer |
| title_short | Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer |
| title_sort | systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer |
| url | http://psasir.upm.edu.my/id/eprint/117874/ http://psasir.upm.edu.my/id/eprint/117874/ http://psasir.upm.edu.my/id/eprint/117874/ http://psasir.upm.edu.my/id/eprint/117874/1/117874.pdf |